Welcome to our dedicated page for Synaptogenix news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix stock.
Synaptogenix Inc (SNPX) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders through its pioneering bryostatin research. This page serves as the definitive source for verified updates on clinical trials, regulatory developments, and scientific partnerships.
Investors and researchers will find comprehensive coverage of the company's progress in Alzheimer's research, multiple sclerosis studies, and orphan drug designations. Key updates include bryostatin-1 trial milestones, strategic academic collaborations, and intellectual property developments.
Our curated news collection features essential updates across three core areas: clinical trial advancements in cognitive disorders, research partnerships with leading neuroscience institutions, and regulatory progress for experimental therapies. This centralized resource eliminates the need to track multiple sources for critical developments.
Bookmark this page for real-time access to Synaptogenix's scientific breakthroughs and business updates. For comprehensive investment research, visit regularly to stay informed about this innovative leader in neurodegenerative disease therapeutics.
Synaptogenix (Nasdaq: SNPX) announced changes to its Scientific Advisory Board (SAB) ahead of the Phase 2b clinical trial data for Bryostatin-1 in advanced Alzheimer's patients. The SAB includes experts such as Dr. George Perry and Dr. Marwan Sabbagh, who will guide the company's therapeutic developments. CEO Alan Tuchman emphasized the critical expertise of the SAB in preparing for the upcoming data. The company has also received Orphan Drug Designation for Bryostatin-1 targeting Fragile X syndrome, enhancing its research credentials.
Synaptogenix, Inc. (Nasdaq: SNPX) announced a corporate update conference call scheduled for July 26, 2022, at 4:30 PM ET. The call will be led by CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, with a live Q&A session following their remarks. The call will discuss updates on the company's development of regenerative therapeutics for neurodegenerative disorders, particularly focusing on Bryostatin-1 for Multiple Sclerosis and Alzheimer's disease. Forward-looking statements regarding clinical trials are included, highlighting potential risks and uncertainties.
Synaptogenix, Inc. (Nasdaq: SNPX) has initiated dosing in its open-label dose optimization clinical trial for Bryostatin-1, aimed at treating Alzheimer's disease (AD). This trial follows promising results from two pilot Phase 2 studies showing significant cognitive improvements over placebo. The company plans to release topline data from its NIH-sponsored Phase 2b trial in Q4 2022. CEO Alan Tuchman expressed optimism about Bryostatin's potential to address synaptic loss, while emphasizing the need for dose optimization to enhance treatment outcomes.
Synaptogenix, a biopharmaceutical company focused on neurodegenerative disorders, announced that Dr. Daniel Alkon will present at the Cell Symposium in Spain on May 17, 2022. The presentation is titled "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." This research aims to extend the therapeutic benefits of Bryostatin for Alzheimer's patients. Currently, the company is conducting a NIH-supported Phase 2 trial for advanced Alzheimer's patients who have shown improvement with Bryostatin treatment.
Synaptogenix, Inc. (Nasdaq: SNPX) has completed enrollment of 100 patients in its NIH-sponsored Phase 2b clinical trial of Bryostatin-1, targeting advanced Alzheimer's disease. Topline results are expected in Q4 2022. The Data Safety Monitoring Board reported no adverse safety issues, suggesting a favorable safety profile for the drug. Past trials indicated significant cognitive enhancement for treated patients. With extended dosing in the current trial, the company anticipates promising outcomes that could lead to further clinical development.
Synaptogenix, Inc. (Nasdaq: SNPX) announced the publication of a peer-reviewed article highlighting Bryostatin's potential to enhance blood vessel health, critical for Alzheimer's disease (AD) treatment. The study, led by researchers from Thomas Jefferson University with NIH collaboration, shows Bryostatin increased micro-vessels in AD mouse models, indicating promise for ongoing Phase 2b clinical trials of Bryostatin-1 in AD patients. The findings emphasize Bryostatin's dual benefits in restoring vascular health and oxidative balance, presenting a hopeful prospect for Alzheimer's care.
Synaptogenix, Inc. (Nasdaq: SNPX) announced Dr. Daniel Alkon's presentation at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on March 29, 2022, at 2 PM ET. His talk focuses on 'Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration.' The company is optimistic about its Phase 2b clinical trial of Bryostatin-1 for advanced Alzheimer's, supported by new peer-reviewed data indicating cognitive restoration. Synaptogenix is committed to developing therapies for neurodegenerative disorders, backed by prior studies on Bryostatin's effects on conditions like Fragile X syndrome.
Synaptogenix (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present on "Regenerative Therapeutics" at the Sachs Neuroscience Innovation Forum on March 22, 2022, at 8 am ET. The company reported promising results from its Phase 2 clinical trial of Bryostatin for advanced Alzheimer's patients, showing significant improvements in cognitive scores. The ongoing NIH-supported Phase 2B trial will further investigate Bryostatin’s effects. Synaptogenix is also planning trials for Fragile X syndrome and multiple sclerosis. Presentation details are available online and via social media.
Synaptogenix, Inc. (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022) on March 15, 2022. His presentation covers the clinical results of Bryostatin in treating advanced Alzheimer’s disease and explores its potential for other neurodegenerative disorders, including Parkinson’s and multiple sclerosis. Currently, Bryostatin-1 is under a six-month NIH-sponsored trial for Alzheimer’s. This research could broaden the therapeutic applications of Bryostatin-1 beyond Alzheimer’s.
Synaptogenix, Inc. (SNPX) announced plans to develop Bryostatin-1 for treating multiple sclerosis (MS), marking its third indication alongside Alzheimer's disease and Fragile X syndrome. The company will collaborate with the Cleveland Clinic for a clinical trial focused on safety and efficacy. Bryostatin-1 aims to address synaptic loss in MS patients, a gap in existing therapies. This collaboration aligns with Synaptogenix's strategic goal to advance clinical development through partnerships. The company has a significant safety database from prior studies in over 1,500 individuals.
